PyInvesting

Market research

LOGC Contextlogic Inc

OTCQB USD Consumer Cyclical

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
519M
P/E ratio
Not available
Analyst target
5.9
Dividend yield
Not available
Beta
2.07

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 4 months ago

LogicBio Therapeutics, Inc is currently in a long term downtrend where the price is trading 38.2% below its 200 day moving average.

From a valuation standpoint, the stock is 96.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 52.6.

LogicBio Therapeutics, Inc's total revenue rose by inf% to $542K since the same quarter in the previous year.

Its net income has increased by 39.8% to $-7M since the same quarter in the previous year.

Finally, its free cash flow grew by 36.7% to $-8M since the same quarter in the previous year.

Based on the above factors, LogicBio Therapeutics, Inc gets an overall score of 4/5.